UCLA Study Finds Rapamycin Reverses Autism-Like Traits in Adult Mice

According to Genengnews, the research indicates that while maternal inflammation during pregnancy can trigger lasting developmental disruptions in offspring, the adult brain may retain a capacity for functional normalization.

Mechanism of Action: Functional vs. Structural Changes

The research team simulated maternal immune activation by exposing pregnant mice to a low dose of a bacterial molecule. This process induced mild inflammation, which resulted in offspring that developed chronic body-wide and brain inflammation, mild brain overgrowth, and overactive cell-signaling in the mTOR pathway—a pathway known to regulate cell growth and proliferation. As these mice reached adulthood, they exhibited traits mirroring human autism, including social difficulties, repetitive behaviors, and intense sensory over-sensitivity.

When adult mice were administered a single injection of rapamycin at 5 mg/kg, researchers observed rapid improvements across nearly every measure within approximately two hours. As reported by UCLA Health, this timeframe is too short to be explained by physical rewiring or the growth of new brain connections. Instead, gene activity analysis revealed that rapamycin reversed abnormal gene expression tied to epilepsy, ion channel function, and autism, particularly within excitatory neurons. The drug appears to work by rebalancing brain cell excitability rather than repairing structural brain differences.

Implications for Future Autism Research

The study suggests that future therapeutic approaches might focus on the brain’s functional circuitry rather than attempting to correct permanent physical anatomical changes.

If the adult brain remains capable of functional normalization, then some features of autism may be successfully addressed without needing to correct underlying structural differences, stated Dr. Janel Le Belle, the paper’s first author and an associate professor in the UCLA Department of Neurosurgery, as noted by Technology Networks.

Harley Kornblum, director of the UCLA Intellectual and Developmental Disabilities Research Center in the Semel Institute for Neuroscience and Human Behavior, added that the results suggest the adult brain is more adaptable than previously assumed.

Limitations Regarding Human Therapy

While the study offers significant insights into the neurobiology of autism, the researchers emphasized that rapamycin is not a viable candidate for broad human therapy. The benefits observed in the study were temporary, with behavioral abnormalities returning fully after 72 hours. Furthermore, Neuroscience News reports that repeated dosing of rapamycin resulted in a loss of efficacy due to tolerance build-up.

Beyond the issue of temporary results, rapamycin is a potent growth inhibitor with the potential for toxicity and immune suppression, making it unsuitable for clinical use in humans. The researchers intend for these findings to redirect future therapeutic efforts toward targeting neuronal excitation and inhibition, as well as sensory circuit neuromodulation, rather than advocating for the direct application of rapamycin in clinical settings.